The remarkable therapeutic efficacy of anti‐CD80/CD86 mAbs in preventing immune activation post‐Treg depletion raised the possibility that blockade of the delivery of co‐stimulatory signals may be used to treat ongoing autoimmunity secondary to complete deletion of Treg or dysfunctional Treg. This evidence concerns the gene CD86 and Autoimmunity.